Efficacy of topical gabapentin in women with primary macular amyloidosis: A side-by-side triple-blinded randomized clinical trial.
J Cosmet Dermatol
; 23(5): 1677-1684, 2024 May.
Article
de En
| MEDLINE
| ID: mdl-38291677
ABSTRACT
BACKGROUND:
Primary cutaneous macular amyloidosis (PCMA) is a chronic pruritic cutaneous disease characterized by heterogeneous extracellular deposition of amyloid protein in the skin.AIMS:
This study aimed to evaluate the efficacy of topical 6% gabapentin cream for the treatment of patients with PCMA. MATERIALS ANDMETHODS:
In this triple-blind clinical trial, a total of 34 patients, who were diagnosed with PCMA, treated using two different strategies of topical gabapentin as the active group and vehicle cream as the control group.RESULTS:
Pruritus score reduction in both groups was statistically significant compared with the baseline value (p < 0.001). There was a significant pigmentation score reduction in intervention group compared with control group after 1 month of the study (p < 0.001). The differences of pigmentation score changes between the groups were not significant at month 2 (p = 0.52) and month 3 (p = 0.22).CONCLUSIONS:
The results of this study suggest that topical gabapentin cream may be effective as a topical agent in the treatment of pruritus associated with PCMA without any significant adverse effects. It is recommended to perform similar studies with a larger sample size and longer duration in both sexes.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Prurit
/
Amyloïdose familiale
/
Gabapentine
Type d'étude:
Clinical_trials
Limites:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Langue:
En
Journal:
J Cosmet Dermatol
Sujet du journal:
DERMATOLOGIA
Année:
2024
Type de document:
Article
Pays d'affiliation:
Iran
Pays de publication:
Royaume-Uni